Edition:
United Kingdom

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

8.80HKD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
HK$8.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,874,038
52-wk High
HK$9.86
52-wk Low
HK$3.95

Chart for

About

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and... (more)

Overall

Beta: --
Market Cap(Mil.): HK$15,675.47
Shares Outstanding(Mil.): 3,321.07
Dividend: --
Yield (%): --

Financials

  2186.HK Industry Sector
P/E (TTM): 15.59 30.93 32.76
EPS (TTM): 0.30 -- --
ROI: 13.25 15.07 14.61
ROE: 13.61 16.60 16.34

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million (396.8 million pounds), as part of a strategy to focus on other therapy areas.

08 May 2018

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

08 May 2018

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 mln

LONDON, May 8 British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

08 May 2018

BRIEF-Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR

* ANNOUNCES ACQUISITION OF ASTRAZENECA'S RIGHTS RELATING TO SEROQUEL AND SEROQUEL XR IN CHINA AND IN OTHER TERRITORIES

07 May 2018

BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China

* LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​

* ‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​ Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-Luye Pharma Group Announces collaboration With Excel Biopharma

* Immuno-Oncology Antibody Drug Development Collaboration With Excel Biopharm

21 Mar 2018

BRIEF-Luye Pharma Group Says ‍Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials​

* ‍ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS​ Source text for Eikon: Further company coverage:

12 Mar 2018

BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug

* ‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG Source text for Eikon: Further company coverage:

26 Feb 2018

BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug

* FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004

21 Feb 2018

Earnings vs. Estimates